RxDoctor Payments Data

Kelsey Rea, PA

Physician Assistant · Raleigh, NCNPI 1548817000

Payments from drug & device makers

$10,576in general payments, 2019–2025

Across 542 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$827
  • Pfizer$681
  • Ardelyx, Inc.$632
  • Takeda Pharmaceuticals U.S.A., Inc.$580
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,40998%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,576 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,066
Medicare patients
334
Services billed
2,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase107$315,665
LinzessLinaclotide113$127,395
ZenpepLipase/Protease/Amylase27$90,456
IbsrelaTenapanor Hcl19$39,216
MotegrityPrucalopride Succinate13$16,787
TrulancePlecanatide19$14,571
Mesalamine34$10,485
Mesalamine ErMesalamine30$8,149
Ursodiol33$6,559
Colestipol Hcl76$6,557
Sucralfate72$6,139
Budesonide DrBudesonide15$4,459
Pantoprazole Sodium233$2,759
Lubiprostone12$2,686
Omeprazole201$2,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,699$443,060220 claims
Aimmune Therapeutics, Inc.Zenpep$208$90,45627 claims
Ardelyx, Inc.Ibsrela$632$39,21619 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$580$16,78713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,095$14,57119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →